We examined effects of carfilzomib-dexamethasone (Kd56) versus bortezomib-dexamethasone (Vd) on health-related quality of life (HR-QoL) in relapsed/refractory multiple myeloma (MM) patients from the ENDEAVOR study. HR-QoL was assessed by the European Organisation for Research and Treatment of Cancer QoL Questionnaire (QLQ-C30), MM-specific module (QLQ-MY20), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-Ntx) "Additional Concerns" neurotoxicity subscale. The QLQ-C30 Global Health Status (GHS)/QoL scale and seven prespecified subscales were compared between groups using mixed model for repeated measures. Of 929 randomized patients, 911 with ≥1 post-baseline assessment were included. Kd56 was associated with statistically significant improvements in GHS/QoL, fatigue, pain, side effects, and FACT/GOG-Ntx scores versus Vd, although mean differences did not meet thresholds for clinical significance. The Kd56 group had longer time to deterioration (TTD) in GHS/QoL (median 3.7 versus 2.8 months, p = 0.0046), physical function (5.6 versus 3.7 months, p = 0.0390), nausea/vomiting (17.6 versus 8.2 months, p = 0.0358), side effects (6.4 versus 3.7 months p < 0.0001), and FACT/GOG-Ntx (11.1 versus 5.5 months, p = 0.0004). Overall, Kd56 resulted in statistically but not clinically significant improvements in mean GHS/QoL scores versus Vd. Treatment with Kd56 versus Vd also significantly prolonged TTD in GHS/QoL, physical function, nausea/vomiting, side effects, and FACT/GOG-Ntx.

Amgen Inc Thousand Oaks CA USA

KCStats Consultancy Leeds UK

National and Kapodistrian University of Athens School of Medicine Athens Greece

The Institute of Cancer Research London UK

Universitatsklinikum Tubingen Tubingen Germany

University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic

University Hospital Salamanca Salamanca Spain

University of Nantes Nantes France

Wilhelminen Cancer Research Institute Wilhelminenhospital Vienna Austria

Zobrazit více v PubMed

Kumar SK, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128. doi: 10.1038/leu.2013.313. PubMed DOI PMC

Sonneveld P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27:1959–1969. doi: 10.1038/leu.2013.185. PubMed DOI PMC

Gulbrandsen N, et al. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur. J. Haematol. 2004;72:172–180. doi: 10.1046/j.0902-4441.2003.00195.x. PubMed DOI

Kvam, A. K. & Waage, A. Health-related quality of life in patients with multiple myeloma–does it matter? Haematologica100, 704–705 (2015). PubMed PMC

Dimopoulos MA, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38. doi: 10.1016/S1470-2045(15)00464-7. PubMed DOI

Dimopoulos MA, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327–1337. doi: 10.1016/S1470-2045(17)30578-8. PubMed DOI

Bjordal K, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur. J. Cancer. 2000;36:1796–1807. doi: 10.1016/S0959-8049(00)00186-6. PubMed DOI

Stead ML, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br. J. Haematol. 1999;104:605–611. doi: 10.1046/j.1365-2141.1999.01206.x. PubMed DOI

Calhoun EA, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int. J. Gynecol. Cancer. 2003;13:741–748. doi: 10.1111/j.1525-1438.2003.13603.x. PubMed DOI

Cocks K, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur. J. Cancer. 2007;43:1670–1678. doi: 10.1016/j.ejca.2007.04.022. PubMed DOI

Kvam AK, Wisloff F, Fayers PM. Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma. Health Qual. Life Outcomes. 2010;8:79. doi: 10.1186/1477-7525-8-79. PubMed DOI PMC

Wisloff F, et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br. J. Haematol. 1996;92:604–613. doi: 10.1046/j.1365-2141.1996.352889.x. PubMed DOI

Lee SJ, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br. J. Haematol. 2008;143:511–519. PubMed

Dubois D, et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J. Clin. Oncol. 2006;24:976–982. doi: 10.1200/JCO.2005.04.0824. PubMed DOI

Siegel DS, et al. Impact of carfilzomib on health-related quality of life: results from a phase 2 post-hoc analysis of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Haematologica. 2015;100:574.

Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat. Med. 2009;28:2509–2530. doi: 10.1002/sim.3639. PubMed DOI

Mallinckrodt C., Lipkovich I. Analyzing Longitudinal Clinical Trial Data: A Practical Guide (CRC Press, Taylor & Francis Group, Danvers, MA, 2016).

Patrick DL, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10:S125–S137. doi: 10.1111/j.1524-4733.2007.00275.x. PubMed DOI

Cocks K, et al. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J. Clin. Oncol. 2011;29:89–96. doi: 10.1200/JCO.2010.28.0107. PubMed DOI

Delforge M, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012;89:16–27. doi: 10.1111/j.1600-0609.2012.01788.x. PubMed DOI

Dimopoulos MA, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013;98:784–788. doi: 10.3324/haematol.2012.074534. PubMed DOI PMC

Stewart, A. K. et al. Health-related quality of life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma.J. Clin. Oncol. (2016). 10.1200/JCO.2016.66.9648. PubMed PMC

Yost KJ, et al. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J. Clin. Epidemiol. 2005;58:1241–1251. doi: 10.1016/j.jclinepi.2005.07.008. PubMed DOI

Cocks K., Buchanan J. Defining responders on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (30-item core module) (QLQ-C30) subscales. Presented at 22nd Annual Conference for the International Society for Quality of Life Research. (Vancouver, Canada, 2015).

Cocks K, et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur. J. Cancer. 2012;48:1713–1721. doi: 10.1016/j.ejca.2012.02.059. PubMed DOI

Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Living with multiple myeloma: experiences of patients and their informal caregivers. Support. Care Cancer. 2011;19:101–111. doi: 10.1007/s00520-009-0793-1. PubMed DOI

Potrata B, et al. Understanding distress and distressing experiences in patients living with multiple myeloma: an exploratory study. Psychooncology. 2011;20:127–134. doi: 10.1002/pon.1715. PubMed DOI

Stephens M, McKenzie H, Jordens CF. The work of living with a rare cancer: multiple myeloma. J. Adv. Nurs. 2014;70:2800–2809. doi: 10.1111/jan.12430. PubMed DOI

DeMuro C, et al. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010. Value Health. 2012;15:443–448. doi: 10.1016/j.jval.2012.01.010. PubMed DOI

Mols F, et al. Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur. J. Haematol. 2012;89:311–319. doi: 10.1111/j.1600-0609.2012.01831.x. PubMed DOI

Delforge M, et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Hematologica. 2015;100:826–833. doi: 10.3324/haematol.2014.120121. PubMed DOI PMC

Bringhen S, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745–4753. doi: 10.1182/blood-2010-07-294983. PubMed DOI

Moreau P, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–440. doi: 10.1016/S1470-2045(11)70081-X. PubMed DOI

Bell, M. L. et al. Differential dropout and bias in randomized controlled trials: when it matters and when it may not. Br. Med. J.346, e8668 (2013). PubMed PMC

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life